EGL-003 Phase 1 SAD Study – Data Results and KOL Perspective Webcast

Date : 1 October 2026
Location : Virtual (on-demand webcast)

Egle Therapeutics will host a webcast reviewing new Phase 1 data for EGL-003, our Treg-selective IL-2 program in atopic dermatitis, featuring independent clinical perspective from Prof. Stephan Weidinger, MD, PhD.

Link to webcast : https://edge.media-server.com/mmc/p/j8kngso9